CXCR4 and neoplasm: CXCR4-A-armed virotherapy followed by FL-mediated expansion of CD103+ DCs prior to vaccination was most effective in inhibiting tumor growth (median survival of 69 days; Figure 6E) and inducing WT1-2Db/RMFPNAPYL tetramer+CD8+ TILs (Figures 6F and 6G).